---
title: "XJZY: Injectable Vecuronium Bromide is expected to be selected for centralized procurement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263207288.md"
description: "According to the Zhitong Finance APP, XJZY announced that the company participated in the bidding work for the 11th batch of national centralized drug procurement organized by the National Organization for Drug Procurement Office from October 27 to October 28, 2025. The company's product, Vecuronium Bromide for Injection, is expected to be selected in this centralized procurement. The indications for this drug are: primarily as an adjunct to general anesthesia, used for tracheal intubation during general anesthesia and muscle relaxation during surgery"
datetime: "2025-10-29T04:04:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263207288.md)
  - [en](https://longbridge.com/en/news/263207288.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263207288.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/263207288.md) | [繁體中文](https://longbridge.com/zh-HK/news/263207288.md)


# XJZY: Injectable Vecuronium Bromide is expected to be selected for centralized procurement

According to the Zhitong Finance APP, XJZY (002332.SZ) announced that the company participated in the bidding work for the 11th batch of national centralized drug procurement organized by the National Organization for Drug Procurement Office from October 27 to October 28, 2025. The company's product, Vecuronium Bromide for Injection, is expected to be selected in this centralized procurement. The indications for this drug are: primarily as an adjunct to general anesthesia, used for tracheal intubation during general anesthesia and muscle relaxation during surgery

### Related Stocks

- [XJZY (002332.CN)](https://longbridge.com/en/quote/002332.CN.md)

## Related News & Research

- [Changchun High-Tech Industry Files Clinical Trial Application for GenSci161 Injection](https://longbridge.com/en/news/277574518.md)
- [Glenmark Pharmaceuticals Unit to Launch Sodium Phosphates Injection](https://longbridge.com/en/news/277144458.md)
- [Vial Doses First Patient for Phase 1 Trial of Vial’s IL-13 x TSLP, a Novel Bispecific Antibody](https://longbridge.com/en/news/277585325.md)
- [08:00 ETBluesight Partners with GraphiteRx and Mark Cuban Cost Plus Drugs to Expand Access to Cost-Saving Medication Sources](https://longbridge.com/en/news/277625153.md)
- [08:15 ETDictionary.com's 2026 Winter Word Drop Embraces Innovation, Goes Global and Enters the Chat](https://longbridge.com/en/news/277470747.md)